Morepen Laboratories approves hiving off of medical devices business

The Board of Directors of Morepen Laboratories Limited has considered and approved the hiving off the Medical Devices Business, being an undertaking, to Morepen Medtech Limited, a subsidiary of the company, on a 'slump sale' basis as a going concern. This hiving off is subject to the receipt of requisite regulatory approvals, including approval of the members of the company.

Glenmark Life Sciences Limited

The name and symbol of Glenmark Life Sciences Limited has changed to Alivus Life Sciences Limited and ALIVUS with effect from January 20, 2025.

 Gland Pharma Limited

Gland Pharma Limited has informed that Shyamakant Giri will assume the office of Chief Executive Officer (CEO) of the company with effect from January 16, 2025. Srinivas Sadu will continue to be the Executive Chairman of the company and support the company’s next phase of growth.

Shalby Limited

Shalby Limited has announced that Shalby Advanced Technologies (SAT) Inc., USA, a step down subsidiary of the company has received US Food and Drug Administration (FDA) 510(k) Premarket Notification Clearance for Duraniom, our Primary Total Knee Replacement device with TiNbN coating, on January 14, 2025. Based on the safety and effectiveness data, FDA has determined the device is substantially equivalent to legally marketed predicate devices.